NASDAQ$ICUI

ICU Medical Inc. · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

ICU Medical's first quarter results were generally in line with expectations.

ICU Medical reported first quarter revenue of $566.7 million, a slight decrease compared to $568.6 million in the same period last year. The company's GAAP net loss was $(39.5) million, or $(1.63) per diluted share, compared to a net loss of $(9.8) million, or $(0.41) per diluted share, for the first quarter of 2023. Adjusted diluted earnings per share were $0.96, down from $1.74 in the prior year.

  • First quarter revenue was $566.7 million, slightly lower than $568.6 million in the same period last year.
  • GAAP gross profit was $185.2 million, compared to $192.0 million in the prior year.
  • GAAP net loss was $(39.5) million, or $(1.63) per diluted share, compared to $(9.8) million, or $(0.41) per diluted share, in the first quarter of 2023.
  • Adjusted EBITDA was $78.8 million, down from $102.0 million in the first quarter of 2023.

Headline financials

Total Revenue

$567M

Previous: $569M-0.4%
EPS

-$1.63

Previous: $1.74-193.7%
Adjusted EBITDA

$78.8M

Previous: $102M-22.7%
GAAP Gross Margin

33.0%

Previous: 34.0%-2.9%
Capital Expenditures

-$15.9M

Previous: -$14.2M-12.0%
Free Cash Flow

-$55.4M

Previous: -$24M-130.6%
Net Income

-$39.5M

Previous: -$9.81M-302.3%
Operating Income

-$10.7M

Previous: $9.4M-213.4%
Gross Profit

$185M

Previous: $192M-3.5%
Total Assets

$4.29B

Previous: $4.47B-4.1%
R&D Expense

$21.8M

No prior period
Stock-Based Comp

$11.6M

Previous: $9.16M+26.6%

Revenue & EPS history

ICU Medical · Revenue · Quarterly

$567M

Q1 2024-0.4%vs Q1 2023
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

ICU Medical · $391M total across 2 segments · Q3 2023

  • Consumables
    $242M+71.5%
  • Infusion Systems
    $149M+69.7%

Forward guidance

ICU Medical provided its fiscal year 2024 outlook.

Tailwinds

  • Interest, net: 105 million
  • Stock compensation expense: 40 million
  • Depreciation and amortization expense: 229 million
  • Restructuring, strategic transaction and integration: 40 million
  • Quality and regulatory initiatives and remediation: 45 million

Headwinds

  • GAAP net loss: $(127) million to $(110) million
  • GAAP diluted loss per share: $(5.16) to $(4.46)
  • Stock compensation expense: 1.63
  • Tax expense from valuation allowance: 1.49
  • Estimated income tax impact from adjustments: (2.55)

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+0.3%

Avg return

Earnings day

-1.1%

Avg return

5 days after

-0.3%

Avg return

30 days after

52%

38 / 73 earnings

Positive

+22.4%

Q2 2024

Best reaction

-33.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.8%-0.8%+10.7%
Q4 2025+4.8%+3.6%-16.3%
Q3 2025+8.2%+7.3%+9.9%
Q1 2025-3.3%-4.9%-6.9%
Q4 2024-2.3%-4.1%-6.4%
Q3 2024-1.9%-5.8%-7.1%
Q2 2024+22.4%+19.7%+31.2%
Q1 2024-0.1%+6.3%+7.6%
Q4 2023+6.5%-0.2%+1.6%
Q3 2023-17.8%-20.2%-15.9%
Q2 2023-15.2%-15.6%-16.8%
Q1 2023+13.3%+8.7%+3.9%
Q4 2022-3.6%-4.2%-7.3%
Q3 2022+6.7%+21.4%+11.8%
Q2 2022-7.4%-4.7%-8.0%
Q1 2022-10.4%-15.0%-14.9%
Q4 2021+5.8%+9.0%+4.3%
Q3 2021+2.1%+2.7%-6.4%
Q2 2021+0.7%+1.2%+6.1%
Q1 2021-5.0%-6.5%-2.1%
Q4 2020-5.5%-6.8%-4.4%
Q3 2020+0.6%+4.8%+5.6%
Q2 2020+8.8%+5.0%+9.8%
Q1 2020-8.8%-13.7%-8.0%
Q4 2019-4.2%-4.8%-8.2%
Q3 2019+6.9%+4.3%+6.8%
Q2 2019-33.3%-31.2%-36.6%
Q1 2019-2.7%-3.3%-2.2%
Q4 2018+2.5%-4.9%-2.8%
Q3 2018-10.6%-14.8%-10.6%
Q2 2018+2.2%+2.4%+3.7%
Q1 2018+1.4%+4.3%+12.4%
Q4 2017+4.6%+7.5%+9.1%
Q3 2017+8.6%+10.1%+11.7%
Q2 2017-2.9%-2.4%+3.4%
Q1 2017-0.2%-0.1%+6.2%
Q4 2016+0.7%-1.0%+1.5%
Q3 2016-0.4%-0.9%+2.5%
Q2 2016+7.5%+6.1%+8.6%
Q1 2016-1.0%
Q4 2015-8.7%
Q3 2015+5.8%
Q2 2015+19.9%
Q1 2015+7.3%
Q4 2014+2.2%
Q3 2014+13.6%
Q2 2014+10.5%
Q1 2014+3.3%
Q4 2013+0.1%
Q3 2013+3.0%
Q2 2013-6.7%
Q1 2013+1.3%
Q4 2012+1.1%
Q3 2012+3.7%
Q2 2012-0.2%
Q1 2012+0.8%
Q4 2011+1.9%
Q3 2011+0.2%
Q2 2011-3.9%
Q1 2011+2.2%
Q4 2010+0.1%
Q3 2010-0.9%
Q2 2010+3.4%
Q1 2010-1.0%
Q4 2007-1.0%
Q4 2009-1.0%
Q3 2009-0.8%
Q3 2008-0.8%
Q2 2009-0.6%
Q2 2008-3.9%
Q1 2009-3.9%
Q4 2008-3.9%
Q1 2008-3.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro